Hereditary Renal Glycosuria, Diabetes, and Responses to SGLT2 Inhibitor

被引：0
|
作者：
Ren, Qian
Gong, Siqian
Han, Xueyao
Ji, Linong
机构：
来源：
DIABETES | 2021年 / 70卷
关键词：
D O I：
10.2337/db21-774-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
774-P
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Considerations for SGLT2 inhibitor use in post-transplantation diabetes
    Hecking, Manfred
    Jenssen, Trond
    NATURE REVIEWS NEPHROLOGY, 2019, 15 (09) : 525 - 526
  • [42] A Novel Therapeutic Agent for Type 2 Diabetes Mellitus: SGLT2 Inhibitor
    Jung, Chang Hee
    Jang, Jung Eun
    Park, Joong-Yeol
    DIABETES & METABOLISM JOURNAL, 2014, 38 (04) : 261 - 273
  • [43] TOFOGLIFLOZIN: A HIGHLY SELECTIVE SGLT2 INHIBITOR FOR THE TREATMENT OF TYPE 2 DIABETES
    Rosenwasser, R. F.
    Rosenwasser, J. N.
    Sutton, D.
    Choksi, R.
    Epstein, B.
    DRUGS OF TODAY, 2014, 50 (11) : 739 - 745
  • [44] The effect of SGLT2 inhibitor in patients with type 2 diabetes and atrial fibrillation
    Cho, Yongin
    Shin, Sung-Hee
    Park, Min-Ae
    Suh, Young Ju
    Park, Sojeong
    Jang, Ji-Hun
    Kim, Dae-Young
    Kim, So Hun
    PLOS ONE, 2025, 20 (02):
  • [45] Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration
    Marko Škrtić
    Gary K. Yang
    Bruce A. Perkins
    Nima Soleymanlou
    Yuliya Lytvyn
    Maximilian von Eynatten
    Hans J. Woerle
    Odd Erik Johansen
    Uli C. Broedl
    Thomas Hach
    Melvin Silverman
    David Z. I. Cherney
    Diabetologia, 2014, 57 : 2599 - 2602
  • [46] Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration
    Skrtic, Marko
    Yang, Gary K.
    Perkins, Bruce A.
    Soleymanlou, Nima
    Lytvyn, Yuliya
    von Eynatten, Maximilian
    Woerle, Hans J.
    Johansen, Odd Erik
    Broedl, Uli C.
    Hach, Thomas
    Silverman, Melvin
    Cherney, David Z. I.
    DIABETOLOGIA, 2014, 57 (12) : 2599 - 2602
  • [47] Mode of SGLT inhibition by an SGLT2 inhibitor, canagliflozin and implication in renal and small intestinal effects
    Kuriyama, Chiaki
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2016, 130 (03) : S22 - S22
  • [48] Update on SGLT2 Inhibitor Warning
    Voelker, Rebecca
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2016, 315 (03): : 243 - 243
  • [49] The SGLT2 inhibitor empagliflozin does not stimulate compensatory appetite responses in patients with excess adiposity and type 2 diabetes
    Davies, M. J.
    Baldry, E. L.
    Bodicoat, D. H.
    Chatterjee, S.
    Edwardson, C. L.
    Gray, L. J.
    Khunti, K.
    Sargeant, J. A.
    Stensel, D. J.
    Webb, D. R.
    Wilding, J. P. H.
    Willis, S. A.
    Yates, T.
    King, J. A.
    DIABETOLOGIA, 2020, 63 (SUPPL 1) : S116 - S116
  • [50] Prolonged ketosis and glycosuria secondary to SGLT2 inhibitor therapy (vol 9, e05057, 2021)
    Bobrowski, D.
    Kumar, R.
    Wu, P. E.
    Lapointe-Shaw, L.
    CLINICAL CASE REPORTS, 2021, 9 (11):
12345